Intravenous immunoglobulin in dermatology

Indian Journal of Dermatology

Volumn 54, Issue 1, 2009, Pages 77-79

  Dhar, Sandipan ^a,b  

^a AMRI HOSPITALS   (India)

^b NONE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ACUTE KIDNEY FAILURE; ALOPECIA; ARTICLE; ASEPTIC MENINGITIS; ATOPIC DERMATITIS; BACKACHE; BLOOD PLACENTA BARRIER; BULLOUS PEMPHIGOID; BULLOUS SKIN DISEASE; CHILL; CHRONIC URTICARIA; CONNECTIVE TISSUE DISEASE; DEEP VEIN THROMBOSIS; DERMATOLOGY; DERMATOMYOSITIS; DRUG APPROVAL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG MILK LEVEL; DRUG MONITORING; DRUG PENETRATION; EPIDERMOLYSIS BULLOSA ACQUISITA; ERYTHEMA MULTIFORME; FEVER; FLUSHING; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; IMMUNOTHERAPY; INJECTION SITE DERMATITIS; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PHLEBITIS; LEUKOCYTOCLASTIC VASCULITIS; LICHENOID ERUPTION; MUCOCUTANEOUS LYMPH NODE SYNDROME; MUCOUS MEMBRANE PEMPHIGOID; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; PEMPHIGOID GESTATIONIS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PETECHIA; PRURITUS; PYODERMA GANGRENOSUM; RECOMMENDED DRUG DOSE; SCLEROMYXEDEMA; SIDE EFFECT; STROKE; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VOMITING;

EID: 64349115476     PISSN: 00195154     EISSN: 19983611     Source Type: Journal    
DOI: 10.4103/0019-5154.48996     Document Type: Article

References (19)

1. Buckley RH, Schiff RI. The use of intravenous immunoglobulin in immunodeficiency diseases. N Engl J Med 1991;325:110-7.
2. Colsky AS. Intravenous immunoglobulin in autoimmune and inflammatory dermatoses: A review of proposed mechanisms of action and therapeutic applications. Dermatol Clin 2000;18:447-57.
3. Fernandez AP, Kerdel FA. The use of i.v. IG therapy in dermatology. Dermatol Ther 2007;20:288-305.
4. Jolles S, Hughes J, Whittaker S. Dermatological uses of highdose intravenous immunoglobulin. Arch Dermatol 1998;134:80-6.
5. Dahl MV, Bridges AG. Intravenous immunoglobulin: Fighting antibodies with antibodies. J Am Acad Dermatol 2001;45:775-83.
6. Ahmed AR, Dahl MV. Consensus statement in the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering disease. Arch Dermatol 2003;139:1051-9.
7. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high dose intravenous immune globulin infusion as treatment for Dermatomyositis. N Engl J Med 1993;329:1993-2000.
8. Genereau T, Chosidow O, Danel C, Chérin P, Herson S. High-dose intravenous immunoglobulin in cutaneous lupus erythematosus. Arch Dermatol 1999;135:1124-5.
9. Parins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, et al. Treatment of toxic epidermal necrolysis with highdose intravenous immunoglobulins: Multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139:26-32.
10. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment toxic epidermal necrolysis using SCORTEN: The university of Miami experience. Arch Dermatol 2003;139:39-43.
11. Schwartz R, Avello E, Palisson F. Lamotrigine-induced toxic epidermal necrolysis treated with intravenous immunoglobulin and amniotic membranes. Arch Dermatol 2008;144:724-6.
12. Bahna SL, Khalili B. New concepts in the management of adverse drug reactions. Allergy Asthma Proc 2007;28:17-24
13. Mittman N, Chan B, Knowles S, Cosentino L, Shear N. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome. Am J Clin Dermatol 2006;7:359-68.
14. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008;58: 33-40.
15. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Steven-Johnson syndrome and toxic epidermal necrolysis: A prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003;139:33-6.
16. Wolff K, Tappeiner G. Treatment of toxic epidermal necrolysis: The uncertainty persists but the fog is dispersing. Arch Dermatol 2003;139:85-6.
17. Jolles S, Hughes J, Whittaker S. Dermatological uses of highdose intravenous immunoglobulin. Arch Dermatol 1998;134:80-6.
18. Rutter A, Luger TA. High-dose intravenous immunoglobulins: A promising approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol 2001;44:1010-24.
19. Katz KA, Hivnor CM, Geist DE, Shapiro M, Ming ME, Werth VP. Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. Arch Dermatol 2003;139:991-3.